Key facts
- Notable investors include Merck Digital Sciences Studio, XEIA Venture Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Forecast (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Forecast (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Forecast (Drug Discovery)
Operator of a drug development company intended to develop brain drugs via astrocyte insights. The company is currently operating in Stealth Mode.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Website
- forecast.bio/
- Ownership
- Privately Held (backing)
Forecast (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Forecast (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Forecast (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.